Exacerbation of symptoms of rheumatoid arthritis in the course of immunotherapy of non-small cell lung cancer - an analysis of medical cases and a review of the literature
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.099Keywords
oncology, immunotherapy, lung cancer, rheumatic diseasesAbstract
Background: Lung cancer has been at the forefront of cancers with the highest incidence and mortality rates. Nowadays, there are available more effective forms of treatment such as immunotherapy. In the case of cancer cells expressing the PD-L1 receptor, pembrolizumab, atezolizumab and nivolmab are of particular use. While these drugs have the great benefit of stabilizing the disease, they are not without side effects, especially inflammatory changes in the joints. The aim of the study is to show the risk of immunotherapy in the form of exacerbation of inflammatory symptoms in patients with rheumatoid arthritis (RA) as a concomitant disease. Case report: Lung cancer (PD-L1 +) was diagnosed in three patients with a history of RA. After meeting the criteria of the drug program, the patients started molecularly targeted therapy with pembrolizumab and atezolizumab. The applied treatment brought a great benefit in the form of stabilization the neoplastic disease. Over time an exacerbation of inflammatory changes within the joints was noted, which significantly impeded everyday functioning in two patients. Due to this situation, immunotherapy was discontinued. Conlusions: Studies show that as many as 1/4 of patients treated with PD-L1 inhibitors experience side effects related to the autoimmune system. In the case of people suffering from RA, the use of immunotherapy may intensify inflammatory changes and increase pain, which significantly reduce the quality of life. Therefore, the risk of RA exacerbation as a side effect of biological therapy for lung cancer treatment should be popularized. This awareness will enable quick intervention and minimize the number of interrupted immunotherapies.
References
Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Jan 9;22(2):612. doi: 10.3390/ijms22020612. PMID: 33435440; PMCID: PMC7827915.
https://immuno-onkologia.pl/wp-content/uploads/2021/06/rak-pluca-2021-Raport.pdf
Wadowska K, Bil-Lula I, Trembecki Ł, Śliwińska-Mossoń M. Genetic Markers in Lung Cancer Diagnosis: A Review. Int J Mol Sci. 2020 Jun 27;21(13):4569. doi: 10.3390/ijms21134569. PMID: 32604993; PMCID: PMC7369725.
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7. PMID: 19423728; PMCID: PMC2927090.
Rendon A, Rayi A. Nivolumab. 2021 Aug 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 33620870.
Flynn JP, Gerriets V. Pembrolizumab. 2021 Jul 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 31536223.
Aleem A, Shah H. Atezolizumab. 2021 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 33620835.
Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62. doi: 10.1158/2326-6066.CIR-14-0191. Epub 2015 May 5. PMID: 25943534.
Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26. PMID: 25722382.
Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. PMID: 25605845; PMCID: PMC4980573.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. PMID: 28885881.
Ghosh N, Tiongson MD, Stewart C, Chan KK, Jivanelli B, Cappelli L, Bass AR. Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. J Clin Rheumatol. 2021 Dec 1;27(8):e317-e322. doi: 10.1097/RHU.0000000000001370. PMID: 32345841; PMCID: PMC7606361.
Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 Published 27 November 2017. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.
Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf. 2018;13(3):150-164. doi: 10.2174/1574886313666180508122332. PMID: 29745339; PMCID: PMC6198478.
Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1751-1763. doi: 10.1002/acr.23177. Epub 2017 Sep 21. PMID: 27998041; PMCID: PMC5478477.
Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017 Jan;76(1):43-50. doi: 10.1136/annrheumdis-2016-209595. Epub 2016 Jun 15. PMID: 27307501; PMCID: PMC5333990.
Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017 Mar 20;3(1):e000412. doi: 10.1136/rmdopen-2016-000412. Erratum in: RMD Open. 2017 Dec 6;3(2):e000412corr1. Kontzias, K [corrected to Kontzias, A]. PMID: 28405474; PMCID: PMC5372131.
Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9. PMID: 28600350.
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10. PMID: 28646772.
Steven NM, Fisher BA. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective. Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii29-vii39. doi: 10.1093/rheumatology/kez536. PMID: 31816079; PMCID: PMC6900910.
Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019 Mar 1;58(3):476-480. doi: 10.1093/rheumatology/key358. PMID: 30508191; PMCID: PMC6821338.
Halls S, Dures E, Kirwan J, Pollock J, Baker G, Edmunds A, Hewlett S. Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology (Oxford). 2015 Apr;54(4):615-22. doi: 10.1093/rheumatology/keu379. Epub 2014 Sep 16. PMID: 25231178; PMCID: PMC4372677.
Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz HM, Hassel JC. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018 Feb;67(2):175-182. doi: 10.1007/s00262-017-2069-9. Epub 2017 Oct 10. PMID: 29018908.
Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, Goldscheider I, Kauffmann-Guerrero D, Huber RM, Dechant C, Berking C, Schulze-Koops H, Skapenko A. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018 Aug 17;4(2):e000714. doi: 10.1136/rmdopen-2018-000714. PMID: 30167328; PMCID: PMC6109812.
Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020 Apr 3;9(4):880. doi: 10.3390/cells9040880. PMID: 32260219; PMCID: PMC7226834.
do Prado AD, Staub HL, Bisi MC, da Silveira IG, Mendonça JA, Polido-Pereira J, Fonseca JE. Ultrasound and its clinical use in rheumatoid arthritis: where do we stand? Adv Rheumatol. 2018 Aug 2;58(1):19. doi: 10.1186/s42358-018-0023-y. PMID: 30657086.
Zayat AS, Ellegaard K, Conaghan PG, Terslev L, Hensor EM, Freeston JE, Emery P, Wakefield RJ. The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. Ann Rheum Dis. 2015 May;74(5):897-903. doi: 10.1136/annrheumdis-2013-204864. Epub 2014 Jan 20. PMID: 24445255.
Yoshimi R, Hama M, Takase K, Ihata A, Kishimoto D, Terauchi K, Watanabe R, Uehara T, Samukawa S, Ueda A, Takeno M, Ishigatsubo Y. Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis. Mod Rheumatol. 2013 May;23(3):456-65. doi: 10.1007/s10165-012-0690-1. Epub 2012 Jul 18. PMID: 22802010.
Iwamoto T, Ikeda K, Hosokawa J, Yamagata M, Tanaka S, Norimoto A, Sanayama Y, Nakagomi D, Takahashi K, Hirose K, Sugiyama T, Sueishi M, Nakajima H. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken). 2014 Oct;66(10):1576-81. doi: 10.1002/acr.22303. PMID: 24515410.
Brzustewicz E, Henc I, Daca A, Szarecka M, Sochocka-Bykowska M, Witkowski J, Bryl E. Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment. Cent Eur J Immunol. 2017;42(3):259-268. doi: 10.5114/ceji.2017.70968. Epub 2017 Oct 30. PMID: 29204090; PMCID: PMC5708207.
Rheumatoid arthritis in adults: management. NICE guideline. Published: 11 July 2018. https://www.nice.org.uk/guidance/ng100
Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol. 2020 May;32(3):315-320. doi: 10.1097/BOR.0000000000000701. PMID: 32168068; PMCID: PMC7212600.
Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20. PMID: 31540935; PMCID: PMC7031780.
Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol. 2017 Dec;12(12):1798-1805. doi: 10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20. PMID: 28939128.
Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925. PMID: 28975219; PMCID: PMC6583041.
Kubiatowski T, Autoimmunologiczne choroby współistniejące u pacjentów onkologicznych poddawanych immunoterapii, portal medycyna praktyczna 2021 https://www.mp.pl/onkologia/nie-tylko-dla-onkologow/show.html?id=262921
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Julia Bargieł, Justyna Cabaj, Izabela Chmielewska, Magdalena Wójcik-Superczyńska, Janusz Milanowski

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 436
Number of citations: 0